James Brugarolas

James Brugarolas at UT Southwestern has contributed to understanding VHL/HIF pathway biology in clear cell renal carcinoma and to translational work leading to belzutifan — a HIF-2alpha inhibitor approved for VHL disease-associated RCC and later for sunitinib-treated metastatic ccRCC. His work connecting VHL loss and HIF activation to targetable dependencies in RCC represents bench-to-bedside translation in this disease.